Cited by 86Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site

Open access
Fang, Zhenhao, Marshall, Christopher B., Nishikawa, Tadateru, Gossert, Alvar D., Jansen, Johanna M., Jahnke, Wolfgang, Ikura, Mitsuhiko·2018·Cell Chemical Biology

Abstract

KRAS is frequently mutated in several of the most lethal types of cancer; however, the KRAS protein has proven a challenging drug target. K-RAS4B must be localized to the plasma membrane by prenylation to activate oncogenic signaling, thus we endeavored to target the protein-membrane interface with small-molecule compounds. While all reported lead compounds have low affinity for KRAS in solution, the potency of Cmpd2 was strongly enhanced when prenylated K-RAS4B is associated with a lipid bilayer. We have elucidated a unique mechanism of action of Cmpd2, which simultaneously engages a shallow pocket on KRAS and associates with the lipid bilayer, thereby stabilizing KRAS in an orientation in which the membrane occludes its effector-binding site, reducing RAF binding and impairing activation of RAF. Furthermore, enrichment of Cmpd2 on the bilayer enhances potency by promoting interaction with KRAS. This insight reveals a novel approach to developing inhibitors of membrane-associated proteins.

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2018.07.009

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NS1 disrupts the self-binding of HRAS and KRAS by directly binding to the α4-α5 interface, reducing activation of downstream pathways and inhibiting cell proliferation.

    “Without interfering with RAS localization and GTPase activity, NS1 disrupts the self-binding of HRAS and KRAS by directly binding to the α4–α5 interface, reducing the activation of downstream pathways and inhibiting cell proliferation [30, 63, 64].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fang, Z., Marshall, C. B., Nishikawa, T., Gossert, A. D., Jansen, J. M., Jahnke, W., & Ikura, M.
Affiliations
  • University Health Network (CA)
  • Novartis (Switzerland) (CH)
  • Novartis Institutes for BioMedical Research (CH)
Corresponding author
  • Marshall, Christopher B.
  • Ikura, Mitsuhiko
Venue
Cell Chemical Biology
Publisher
Elsevier BV
Published
2018-11
Volume
25
Issue
11
Pages
1327-1336.e4
ISSN
  • 2451-9448 (ISSN-L)
  • 2451-9456
OpenAlex
W2886480505
Cited by
86
References
32
Citations by year
2026: 3 · 2025: 4 · 2024: 11 · 2023: 11 · 2022: 7 · 2021: 14 · 2020: 20 · 2019: 12 · 2018: 3
FWCI
4.36
Type
journal article
Language
en
Open access
Locations
  • Cell chemical biology (publishedVersion)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (acceptedVersion)
Funders
  • Canada Foundation for Innovation
  • Connaught Fund
  • Canadian Cancer Society Research Institute (703209)
  • Canadian Institutes of Health Research
  • Princess Margaret Cancer Foundation
  • Cancer Research Society (14014)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
K-Ras4B, prenylation, lipid bilayers, Raf activation, small molecule inhibitors, protein-membrane interface, oncogenic KRAS
MeSH terms
Animals, Antineoplastic Agents, Enzyme Inhibitors, Humans, Indoles, Lipid Bilayers, Models, Molecular, Piperidines, Proto-Oncogene Proteins p21(ras), Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review